Inhibiteur PKA 14-22 μ; perméable à la cellule ; myristoysé

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

Target K_i: 36 nMf or cAMP-dependent protein kinase

Reversible: no

Product does not compete with ATP.

Primary TargetcAMP-dependent protein kinase

Cell permeable: yes

General description

Heat-stable protein kinase inhibitor (PKI) peptide sequence (14-22) that has been myristoylated at the N-terminus, enhancing its cell-permeability. The non-myristoylated version of this peptide is a highly specific inhibitor (K_i = 36 nM) of cAMP-dependent protein kinase (PKA).

Heat-stable protein kinase inhibitor (PKI) peptide sequence (14 - 22) that has been myristoylated at the N-terminus, enhancing its cell-permeability. The non-myristoylated version of this peptide is a highly specific inhibitor (K_i = 36 nM) of cAMP-dependent protein kinase.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Paman, K., et al. 1998. J. Lipid Res. 39, 1091.Rimon, G., and Rubin M. 1998. Biochim. Biophys. Acta 1380, 289.Harris, T.E., et al. 1997. Biochem. Biophys. Res. Commun. 232, 648.Muniz, M., et al. 1997. Proc. Natl. Acad. Sci. USA 94, 14461.Zoukhri, D., et al. 1997. Am. J. Physiol. 272, C263.Eichholtz, T., et al. 1993. J. Biol. Chem.268, 1982.Ward, N.E. and O'Brian, C.A. 1993. Biochemistry32, 11903.Walsh, D.A. and Glass, D.B. 1991. Methods Enzymol. 201, 304.Glass, D.B., et al. 1989. J. Biol. Chem.264, 8802.

Packaging

500 µg in Plastic ampoule

Physical form

Supplied as a trifluoroacetate salt.

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Sequence

Myr-N-Gly-Arg-Thr-Gly-Arg-Arg-Asn-Ala-Ile-NH₂

Warning

Toxicity: Standard Handling (A)